ATE338813T1 - Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen - Google Patents

Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen

Info

Publication number
ATE338813T1
ATE338813T1 AT96908841T AT96908841T ATE338813T1 AT E338813 T1 ATE338813 T1 AT E338813T1 AT 96908841 T AT96908841 T AT 96908841T AT 96908841 T AT96908841 T AT 96908841T AT E338813 T1 ATE338813 T1 AT E338813T1
Authority
AT
Austria
Prior art keywords
tumor treatment
human lymphocytes
lymphocytes
patient
treatment
Prior art date
Application number
AT96908841T
Other languages
English (en)
Inventor
Gale A Granger
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE338813T1 publication Critical patent/ATE338813T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
AT96908841T 1995-03-17 1996-03-15 Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen ATE338813T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40638895A 1995-03-17 1995-03-17

Publications (1)

Publication Number Publication Date
ATE338813T1 true ATE338813T1 (de) 2006-09-15

Family

ID=23607777

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96908841T ATE338813T1 (de) 1995-03-17 1996-03-15 Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen

Country Status (11)

Country Link
US (2) US5837233A (de)
EP (1) EP0815204B1 (de)
JP (1) JP3201610B2 (de)
KR (1) KR19980703072A (de)
AT (1) ATE338813T1 (de)
AU (1) AU696572B2 (de)
BR (1) BR9607894A (de)
CA (1) CA2214503C (de)
DE (1) DE69636514D1 (de)
NO (1) NO974275L (de)
WO (1) WO1996029394A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361332B2 (en) * 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US20080220025A1 (en) * 1995-03-17 2008-09-11 James Thompson Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
ATE229810T1 (de) 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
AU7154598A (en) * 1997-04-23 1998-11-13 Regents Of The University Of California, The A cell strain with activated anti-cancer cytotoxic activity
EP1037643B1 (de) * 1997-10-10 2003-12-03 Meyer Pharmaceuticals, LLC Krebsimmuntherapie mittels allostimulierten zellen zur sequentiellen implantationsstrategie
AU9794698A (en) 1997-10-10 1999-05-03 Regents Of The University Of California, The Enhanced immunogenic cell populations prepared using h2 receptor antagonists
EP1021197B1 (de) 1997-10-10 2007-04-11 The Regents of the University of California Allogene zellkombination enthaltende implantate zur krebsbehandlung
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments
CA2367132A1 (en) 1999-03-24 2000-09-28 Gene M. Shearer Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs)
US6719805B1 (en) * 1999-06-09 2004-04-13 C. R. Bard, Inc. Devices and methods for treating tissue
US20060009393A1 (en) * 1999-10-02 2006-01-12 The Government of the U.S.A as represented by the Secretary of the Dept. of Health & Human Services Immunogenic epitopes for fibroblast growth factors 5 (FGF-5)
WO2001094551A2 (de) * 2000-06-09 2001-12-13 Universitätsklinikum Charite Medizinische Fakultät Der Humboldt-Universität Zu Berlin, Akademische Verwaltung - Forschung Gen-modifizierte t-zellen, verfahren zu ihrer herstellung und ihre verwendung
DE10120505A1 (de) * 2001-04-26 2002-11-07 Rudolf Wank Verwendung von stimulierten mononukleären Zellen des peripheren Blutes zur Behandlung von Krebserkrankungen
US20030003074A1 (en) * 2001-06-14 2003-01-02 Macromed, Inc. Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
US20060159657A1 (en) * 2001-06-14 2006-07-20 Macromed, Incorporated Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
CA2476999C (en) * 2002-02-22 2015-09-15 Intracel Resources Llc Sterile immunogenic non-tumorigenic tumor cell compositions and methods
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US9155789B2 (en) * 2005-04-25 2015-10-13 New York University Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
US8691568B2 (en) 2006-11-22 2014-04-08 Hua Liu Method for preparing cell populations with anti-tumor immune response activity
US20080147007A1 (en) * 2006-12-19 2008-06-19 Toby Freyman Delivery device with pressure control
CN101641010A (zh) 2007-01-26 2010-02-03 路易斯维尔大学研究基金会公司 用作疫苗的外来体组分的修饰
RU2015102067A (ru) * 2009-03-05 2015-06-20 Макрокьюэ, Лтд. Активированная лейкоцитарная композиция
EP2494038B1 (de) * 2009-10-27 2019-06-26 Immunicum AB Verfahren zur proliferation von antigenspezifischen t-zellen
AU2015343239B2 (en) 2014-11-05 2021-06-03 Memorial Sloan Kettering Cancer Center Methods of selecting T cell line and donor thereof for adoptive cellular therapy
WO2018138682A1 (en) 2017-01-26 2018-08-02 Immune Therapeutics Methods and compositions useful for treating cancer
KR102234394B1 (ko) * 2019-03-08 2021-03-31 신지섭 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제
KR102216710B1 (ko) * 2019-03-27 2021-02-17 신지섭 Nk세포배양배지용 첨가조성물, 상기 첨가조성물을 이용한 nk세포배양방법 및 상기 배양방법으로 얻어진 피부트러블개선용 화장료조성물
TWI790399B (zh) * 2019-08-30 2023-01-21 長庚大學 循環腫瘤細胞資訊評估方法及其分析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038145A (en) * 1974-07-08 1977-07-26 Mead Johnson & Company Malignancy diagnostic method
US4677056A (en) * 1983-08-18 1987-06-30 Sloan-Kettering Institute For Cancer Research Monoclonal antibody subsetting human helper and killer T-cells and method
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
US5057423A (en) * 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
WO1992004044A1 (en) * 1990-09-06 1992-03-19 Schering Corporation Use of il-4 to treat solid tumors
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Also Published As

Publication number Publication date
NO974275D0 (no) 1997-09-16
BR9607894A (pt) 1999-06-01
JPH11501656A (ja) 1999-02-09
EP0815204B1 (de) 2006-09-06
DE69636514D1 (de) 2006-10-19
KR19980703072A (ko) 1998-09-05
JP3201610B2 (ja) 2001-08-27
EP0815204A1 (de) 1998-01-07
CA2214503C (en) 2002-05-07
MX9707077A (es) 1998-08-30
WO1996029394A1 (en) 1996-09-26
US6136306A (en) 2000-10-24
NO974275L (no) 1997-10-15
US5837233A (en) 1998-11-17
AU5254796A (en) 1996-10-08
AU696572B2 (en) 1998-09-10
EP0815204A4 (de) 1999-04-14
CA2214503A1 (en) 1996-09-26

Similar Documents

Publication Publication Date Title
ATE338813T1 (de) Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
DE69722426D1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
ES2133413T3 (es) Gel de lecitina inyectable.
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
EP1059929A4 (de) Isolierte stromalzellen zur verwendung in der behandlung von erkrankungen des zentralnervensystems
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69836139D1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
EP0957161A4 (de) Verfahren zur aktivierung von menschlichen, antigen-aktivierenden zellen, aktivierte menschliche, antigen-aktivierende zellen und anwendungen derselben
DE3888273D1 (de) Medizinischer Apparat zur Behandlung mit Ultraschall.
ATE237339T1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
DE69317338D1 (de) Vorrichtung zur Stimulation lebenden Gewebes
ATE221377T1 (de) Verfahren zur reduzierung der körperfettanteils bei tieren mit der verabreichungvon konjugiergter linolsäure
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE332142T1 (de) Zusammensetzungen zur behandlung von tierischen krankheiten und syndromen mit transferfaktor
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
DE3876756D1 (de) Vorrichtung zur gesteuerten freigabe und verabreichung von wirkstoffen an tierisches gewebe.
DE69512760D1 (de) Verwendung von Melatonin zur Behandlung von Patienten die an Drogenabhängigkeit leiden
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE58908604D1 (de) Medizinisches Gerät zur Stimulation eines physiologischen Vorganges eines Lebewesens mit sich selbsttätig an die körperliche Aktivität des Lebewesens anpassender Stimulationsintensiät.
DE58904722D1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
DE69638145D1 (de) Verfahren zur herbeiführung einer immuntoleranz mit hilfe von immuntoxinen
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
ATE59780T1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
ATE167628T1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties